China Resources Sanjiu Medical @ Pharmac&utical Co., Ltd.

The company is a large state-owned listed pharmaceutical company, mainly engaged in R&D, production, sales of pharmaceutical products and related health services. It was listed on the Shenzhen Stock Exchange on March 9, 2000, and officially joined China Resources Group in 2008. China Resources 39's vision is to become the “leader of the popular medicine and health industry” in China, innovate the application of traditional Chinese and Western medicine science and technology, focus on innovative research and development and intelligent manufacturing of high-quality medical and health products, serve every member of the Chinese family, and strive to become the number one medical and health brand in China. The company's products include Hesetong 37 series products, included injections, mitoxantrone hydrochloride injections for tracers, huaxanthin tablets and injections, proxen capsules, blood stasis, and cefpiromate sodium for injection. Corporate honors: The company has been awarded “Top 100 Valuable Companies” and “Top 100 Golden Bulls” by China's main board listed companies many times. Up to now, China Resources 39 has been included in the Shenzhen Stock Exchange Component Index, China Securities 500, MSCI Emerging Markets Index, and FTSE Russell (FTSERussell).